Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-04-22
2008-04-22
Belyavskyi, Michail (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C435S007100
Reexamination Certificate
active
11144744
ABSTRACT:
Studies in mice and humans indicate that membrane CD14 (mCD14) on the cell surface of monocytes, macrophages, and PMN mediates the activation of these cells by LPS. The soluble CD14 (sCD14) present in the circulation also binds to LPS and blocks LPS binding to mCD14. To determine the role of a recombinant bovine soluble CD14 polypeptide in cellular activation by LPS, a recombinant bovine soluble CD14 polypeptide, rbosCD14, was cloned and expressed in a baculovirus expression system. Results indicated that rbosCD14 inhibited the LPS-induced increase in CD18 expression and TNFα mRNA in vitro and reduced mortality in mice injected with LPS. Further, rbosCD14 sensitized mammary epithelial cells to low concentrations of LPS resulting in recruitment of white blood cells and prevention of LPS-induced infection.
REFERENCES:
patent: 5543303 (1996-08-01), Goyert
patent: 5804189 (1998-09-01), Goyert
patent: 5869055 (1999-02-01), Juan et al.
Mikayama et al: (PNAS, 1993. 90: 10056-10060.
Burgess et al (J Cell Biol. 111:2129-2138, 1990.
Lazar et al. Mol Cell Biol. 8:1247-1252, 1988.
Wang et al. JBC, 2001 276:49213-49220.
Haziot, A., et al., “Recombinant Soluble CD14 Inhibits LPS-Induced Tumor Necrosis Factor-α Production by Cells in Whole Blood”,J. of Immunology, vol. 152, pp. 5868-5876, 1994.
Haziot, A., et al., “Recombinant Soluble CD14 Mediates the Activation of Endothelial Cells by Lipopolysaccharide”,J. of Immunology, vol. 151, pp. 1500-1507, 1993.
Haziot, A., et al., “Recombinant Soluble CD14 Prevents Mortality in Mice Treated with Endotoxin (Lipopolysaccharide)”,J. of Immunology, vol. 154, pp. 6529-6532, 1995.
Ikeda, A., et al., “Molecular Cloning of Bovine CD14 gene”,J. Vet. Med. Sci., vol. 59, (8), pp. 715-719, 1997.
Majerle, A., et al., “Expression and Refolding of Functional Fragments of the Human Lipopolysaccharide Receptor CD14 inEscherichia coliandPichia pastoris”, Protein Expression and Purification, vol. 17, pp. 96-104, 1999.
Stelter, F., et al., “Different Efficacy of Soluble CD14 Treatment in High-and Low-Dose LPS Models”,European J. of Clinical Investigation, vol. 28, pp. 205-213, 1998.
Takai, N., et al., “Primary Structure of Rat CD14 and Characteristics of Rat CD14, Cytokine, and NO Synthase mRNA Expression in Mononuclear Phagocyte System Cells in Response to LPS”,J. Of Leukocyte Biology, vol. 61, pp. 736-744, 1997.
Tapping, R.I., et al., “Cellular Binding of Soluble CD14 Requires Lipopolysaccharide (LPS) and LPS-binging Protein”,Department of Immunology, Abstract, vol. 272, (37), pp. 23157-23164, Sep. 12, 1997.
Paape Max J.
Wang Yan
Zarlenga Dante S.
Belyavskyi Michail
Fado John
Rabin Evelyn
The United States of America as represented by the Secretary of
LandOfFree
Method for sensitizing bovine mammary cells to respond to LPS does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for sensitizing bovine mammary cells to respond to LPS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for sensitizing bovine mammary cells to respond to LPS will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3918630